Carregant...
Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
BACKGROUND: Since December 2019, COVID-19 has spread to almost every corner of the world. In theory, tocilizumab and favipiravir are considered to be reliable drugs for the treatment of COVID-19 with elevated IL-6. We aimed to assess the efficacy and safety of tocilizumab combined with favipiravir i...
Guardat en:
| Publicat a: | Biomed Pharmacother |
|---|---|
| Autors principals: | , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Published by Elsevier Masson SAS.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7524677/ https://ncbi.nlm.nih.gov/pubmed/33378989 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.biopha.2020.110825 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|